Compare Stocks: ZBH, PEN, BSX, and EW

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BSX Boston Scientific	$49.19 +3.0%	$45.73	$42.20 ▼ $109.50	$69.19B	0.56	19.72 million shs	21.40 million shs
EW Edwards Lifesciences	$89.33 +0.4%	$88.13	$72.30 ▼ $96.29	$51.23B	0.85	5.29 million shs	2.65 million shs
PEN Penumbra	$324.75 +0.5%	$318.71	$221.26 ▼ $362.41	$12.73B	0.7	396,270 shs	258,261 shs
ZBH Zimmer Biomet	$97.13 -1.0%	$89.89	$79.12 ▼ $108.29	$18.99B	0.45	2.53 million shs	3.00 million shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BSX Boston Scientific	+3.06%	+7.12%	+8.59%	-8.72%	-52.21%
EW Edwards Lifesciences	+0.54%	+2.67%	-5.76%	+11.86%	+13.71%
PEN Penumbra	+0.50%	+1.46%	+2.00%	+0.81%	+35.28%
ZBH Zimmer Biomet	-0.97%	+2.35%	+8.65%	+18.10%	+6.49%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BSX Boston Scientific	$49.19 +3.0%	$45.73	$42.20 ▼ $109.50	$69.19B	0.56	19.72 million shs	21.40 million shs
EW Edwards Lifesciences	$89.33 +0.4%	$88.13	$72.30 ▼ $96.29	$51.23B	0.85	5.29 million shs	2.65 million shs
PEN Penumbra	$324.75 +0.5%	$318.71	$221.26 ▼ $362.41	$12.73B	0.7	396,270 shs	258,261 shs
ZBH Zimmer Biomet	$97.13 -1.0%	$89.89	$79.12 ▼ $108.29	$18.99B	0.45	2.53 million shs	3.00 million shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BSX Boston Scientific	+3.06%	+7.12%	+8.59%	-8.72%	-52.21%
EW Edwards Lifesciences	+0.54%	+2.67%	-5.76%	+11.86%	+13.71%
PEN Penumbra	+0.50%	+1.46%	+2.00%	+0.81%	+35.28%
ZBH Zimmer Biomet	-0.97%	+2.35%	+8.65%	+18.10%	+6.49%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BSX Boston Scientific	2.71	Moderate Buy	$71.62	45.60% Upside
EW Edwards Lifesciences	2.74	Moderate Buy	$100.27	12.25% Upside
PEN Penumbra	2.12	Hold	$367.07	13.03% Upside
ZBH Zimmer Biomet	2.25	Hold	$104.00	7.07% Upside

Current Analyst Ratings Breakdown

Latest ZBH, PEN, BSX, and EW Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/6/2026	ZBH Zimmer Biomet	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$106.00
8/6/2026	ZBH Zimmer Biomet	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$104.00
8/6/2026	ZBH Zimmer Biomet	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$120.00
8/6/2026	ZBH Zimmer Biomet	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Market Perform	$91.00 ➝ $93.00
8/6/2026	ZBH Zimmer Biomet	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Perform	$96.00
8/6/2026	ZBH Zimmer Biomet	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$101.00 ➝ $110.00
8/6/2026	ZBH Zimmer Biomet	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$105.00 ➝ $110.00
8/5/2026	ZBH Zimmer Biomet	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold
8/4/2026	ZBH Zimmer Biomet	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C-)
7/31/2026	BSX Boston Scientific	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
7/30/2026	BSX Boston Scientific	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$85.00 ➝ $70.00

(Data available from 8/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BSX Boston Scientific	$20.07B	3.55	$4.16 per share	11.83	$17.37 per share	2.83
EW Edwards Lifesciences	$6.07B	8.48	$2.86 per share	31.20	$18.63 per share	4.79
PEN Penumbra	$1.50B	8.50	$4.32 per share	75.18	$38.86 per share	8.36
ZBH Zimmer Biomet	$8.23B	2.28	$13.60 per share	7.14	$65.30 per share	1.49

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BSX Boston Scientific	$2.90B	$2.47	19.91	14.38	1.04	17.50%	19.28%	10.89%	N/A
EW Edwards Lifesciences	$1.07B	$1.74	51.34	26.43	2.23	15.43%	15.68%	12.05%	N/A
PEN Penumbra	$177.69M	$4.07	79.79	52.30	2.00	10.67%	10.50%	8.17%	N/A
ZBH Zimmer Biomet	$705.20M	$3.85	23.63	10.90	2.88	9.48%	13.12%	7.23%	N/A

Latest ZBH, PEN, BSX, and EW Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2026	Q2 2026	ZBH Zimmer Biomet	$2.01	$2.07	+$0.06	$1.03	$2.13 billion	$2.18 billion
7/30/2026	Q2 2026	PEN Penumbra	$1.16	$0.88	-$0.28	$0.88	$389.64 million	$390.05 million
7/29/2026	Q2 2026	BSX Boston Scientific	$0.83	$0.86	+$0.03	$0.61	$5.38 billion	$5.44 billion
7/23/2026	Q2 2026	EW Edwards Lifesciences	$0.7430	$0.78	+$0.0370	$0.42	$1.70 billion	$1.74 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BSX Boston Scientific	N/A	N/A	N/A	N/A	N/A
EW Edwards Lifesciences	N/A	N/A	N/A	N/A	N/A
PEN Penumbra	N/A	N/A	N/A	N/A	N/A
ZBH Zimmer Biomet	$0.96	0.99%	N/A	24.94%	N/A

Latest ZBH, PEN, BSX, and EW Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/22/2026	ZBH Zimmer Biomet	quarterly	$0.24	1.06%	6/25/2026	6/25/2026	7/31/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BSX Boston Scientific	0.43	1.24	1.22
EW Edwards Lifesciences	0.06	4.52	3.63
PEN Penumbra	0.01	5.75	3.86
ZBH Zimmer Biomet	0.50	1.69	0.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BSX Boston Scientific	89.07%
EW Edwards Lifesciences	79.46%
PEN Penumbra	88.88%
ZBH Zimmer Biomet	88.89%

Insider Ownership

Company	Insider Ownership
BSX Boston Scientific	0.34%
EW Edwards Lifesciences	0.31%
PEN Penumbra	2.90%
ZBH Zimmer Biomet	1.28%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BSX Boston Scientific	59,000	1.45 billion	1.44 billion	Optionable
EW Edwards Lifesciences	16,000	575.80 million	574.02 million	Optionable
PEN Penumbra	4,700	39.39 million	38.25 million	Optionable
ZBH Zimmer Biomet	17,000	193.46 million	190.99 million	Optionable

ZBH, PEN, BSX, and EW Headlines

Recent News About These Companies

Wilsey Asset Management Inc. Has $36.32 Million Stake in Zimmer Biomet Holdings, Inc. $ZBH

1 hour ago | marketbeat.com

Zimmer Biomet Holdings, Inc. Q2 2026 Earnings Call Summary

3 hours ago | finance.yahoo.com

Zimmer Biomet Holdings (ZBH) Gets a Buy from TD Cowen

August 6 at 6:13 PM | theglobeandmail.com

Zimmer Biomet’s (NYSE:ZBH) Q2 CY2026: Beats On Revenue

August 6 at 6:13 PM | theglobeandmail.com

ZBH Q2 deep dive: US hip strength, product launches, and channel transformation shape outlook

August 6 at 1:13 PM | msn.com

Here's Why Zimmer Biomet (ZBH) is a Strong Value Stock

August 6 at 10:41 AM | zacks.com

Zimmer Biomet (NYSE:ZBH) Price Target Raised to $110.00

August 6 at 10:35 AM | marketbeat.com

Renaissance Technologies LLC Invests $5.47 Million in Zimmer Biomet Holdings, Inc. $ZBH

August 6 at 4:32 AM | marketbeat.com

Bank of America Corp DE Purchases 249,175 Shares of Zimmer Biomet Holdings, Inc. $ZBH

August 6 at 3:20 AM | marketbeat.com

Zimmer Biomet (NYSE:ZBH) Issues Earnings Results

August 5 at 3:10 PM | marketbeat.com

Zimmer Biomet Holdings, Inc. (ZBH) Q2 2026 Earnings Call Transcript

August 5 at 3:00 PM | seekingalpha.com

ZBH's Q2 Earnings Beat, '26 View Raised, Stock Up in Pre-Market

August 5 at 12:51 PM | zacks.com

Zimmer (ZBH) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

August 5 at 10:31 AM | zacks.com

Zimmer: Q2 Earnings Snapshot

August 5 at 9:33 AM | stamfordadvocate.comS

Zimmer Biomet raises guidance on Q2 beats

August 5 at 9:33 AM | massdevice.com

Zimmer Biomet raises full-year outlook after second-quarter earnings beat

August 5 at 9:33 AM | msn.com

Zimmer Biomet’s (NYSE:ZBH) Q2 CY2026 beats on revenue

August 5 at 9:33 AM | msn.com

Zimmer Biomet (ZBH) Q2 Earnings and Revenues Beat Estimates

August 5 at 8:46 AM | zacks.com

Zimmer Biomet (NYSE:ZBH) Updates FY 2026 Earnings Guidance

August 5 at 7:25 AM | marketbeat.com

Zimmer Biomet Announces Second Quarter 2026 Financial Results

August 5 at 6:30 AM | prnewswire.com

Royal Bank of Canada Sells 86,837 Shares of Zimmer Biomet Holdings, Inc. $ZBH

August 5 at 5:03 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ZBH, PEN, BSX, and EW Company Descriptions

Boston Scientific NYSE:BSX

$49.19 +1.45 (+3.03%)

Closing price 08/6/2026 03:59 PM Eastern

Extended Trading

$49.34 +0.15 (+0.30%)

As of 08:09 AM Eastern

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Edwards Lifesciences NYSE:EW

$89.33 +0.36 (+0.40%)

Closing price 08/6/2026 03:59 PM Eastern

Extended Trading

$89.46 +0.13 (+0.14%)

As of 07:56 AM Eastern

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Penumbra NYSE:PEN

$324.75 +1.54 (+0.48%)

Closing price 08/6/2026 03:59 PM Eastern

Extended Trading

$323.99 -0.76 (-0.23%)

As of 08:03 AM Eastern

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

Zimmer Biomet NYSE:ZBH

$97.13 -1.03 (-1.05%)

Closing price 08/6/2026 03:59 PM Eastern

Extended Trading

$97.18 +0.05 (+0.05%)

As of 08:05 AM Eastern

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers robotic, surgical, and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ZBH, PEN, BSX, and EW Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ZBH, PEN, BSX, and EW Earnings

Compare Dividends

Latest ZBH, PEN, BSX, and EW Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ZBH, PEN, BSX, and EW Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ZBH, PEN, BSX, and EW Company Descriptions

Boston Scientific NYSE:BSX

Edwards Lifesciences NYSE:EW

Penumbra NYSE:PEN

Zimmer Biomet NYSE:ZBH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools